Michael Rice - Dec 13, 2021 Form 4 Insider Report for BIOLIFE SOLUTIONS INC (BLFS)

Role
CEO, Director
Signature
/s/ Michael Rice
Stock symbol
BLFS
Transactions as of
Dec 13, 2021
Transactions value $
-$1,050,958
Form type
4
Date filed
12/15/2021, 07:00 PM
Previous filing
Dec 9, 2021
Next filing
Dec 30, 2021

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction BLFS Common Stock Options Exercise $29.7K +16.7K +6.4% $1.78* 277K Dec 13, 2021 Direct
transaction BLFS Common Stock Sale -$564K -16.7K -6.02% $33.82 260K Dec 13, 2021 Direct F1, F2
transaction BLFS Common Stock Options Exercise $29.7K +16.7K +6.4% $1.78* 277K Dec 15, 2021 Direct
transaction BLFS Common Stock Sale -$547K -16.7K -6.02% $32.80 260K Dec 15, 2021 Direct F1, F3

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction BLFS Employee Stock Option Options Exercise $0 -16.7K -16.67% $0.00 83.3K Dec 13, 2021 Common Stock 16.7K $1.78 Direct F4
transaction BLFS Employee Stock Option Options Exercise $0 -16.7K -20% $0.00 66.7K Dec 15, 2021 Common Stock 16.7K $1.78 Direct F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person effective as of December 1, 2020.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.98 to $34.51, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $32.12 to $33.71, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F4 On February 07, 2017, the reporting person was granted an option to purchase 100,000 shares of common stock which vested 25% on the first anniversary of the grant date, and in 36 equal monthly installments thereafter.